Abstract
Background: Patients with chronic spontaneous urticaria (CSU) have spontaneous wheals (W), angioedema (AE), or both, for longer than 6 weeks. Clinical differences between patients with standalone W, standalone AE, and W and AE (W+AE) remain incompletely understood. Objective: To compare W, AE, and W+AE CSU patients regarding demographics, disease characteristics, comorbidities, disease burden, and treatment response. Methods: Baseline data from 3,698 CSU patients in the ongoing, prospective, international, multicenter, observational Chronic Urticaria REgistry (CURE) were analyzed (data cut: September 2022). Results: Across all CSU patients, 59%, 36%, and 5% had W+AE, W, and AE, respectively. The W+AE patients, compared with W and AE patients, showed the lowest male-to-female ratio (0.33), higher rates of concomitant psychiatric disease (17% vs 11% vs 6%, respectively), autoimmune disease (13% vs 7% vs 9%, respectively), and nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity (9% vs 5% vs 2%, respectively) and the highest disease impact. The W patients, compared with W+AE and AE patients, showed the lowest rates of concomitant hypertension (15% vs 21% vs 40%, respectively) and obesity (11% vs 16% vs 17%, respectively), the highest rate of concomitant inducible urticaria (24% vs 22% vs 6%, respectively), and shorter W duration. The AE patients, compared with W+AE and W patients, were older at disease onset, showed longer AE duration, and the best response to increased doses of H1-antihistamines (58% vs 24% vs 31%, respectively) and omalizumab (92% vs 67% vs 60%, respectively). Conclusions: Our findings provide a better understanding of CSU phenotypes and may guide patient care and research efforts that aim to link them to pathogenic drivers.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Journal of Allergy and Clinical Immunology: In Practice |
| Jahrgang | 11 |
| Ausgabenummer | 11 |
| Seiten (von - bis) | 3515-3525.e4 |
| ISSN | 2213-2198 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 11.2023 |
Fördermittel
Conflicts of interest: T. Buttgereit is or recently was a speaker and/or advisor for AstraZeneca, BioCryst, CSL-Behring, GlaxoSmithKline (GSK), Hexal, KalVista, Medac, Novartis, Pharming, Roche, Sanofi, and Takeda, outside the submitted work. M. K. Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, Moxie, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach. M. Bizjak has been a speaker and advisor for Novartis, outside the submitted work. J. Dissemond received payments for consultations, lectures, and studies from Novartis . A.G.A was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen , AstraZeneca , Avene, Celldex , Escient Pharmaceutials, Genentech , GSK , Instituto Carlos III- FEDER , Leo Pharma, Menarini, Novartis , Sanofi – Regeneron , Thermo Fisher Scientific , and Uriach Pharma/Neucor, outside the submitted work. K. Kulthanhan received grants/research supports from Novartis; and honoraria or consultation fees from Novartis, A. Menarini, Takeda, and Sanofi. A. Kaspeska-Zajac has been a speaker for Novartis, outside the submitted work. P. Kolkhir received honoraria (advisory board, speaker) from Roche, Novartis, and Valenza Bio Inc., outside the submitted work. K. Weller received honoraria for educational lectures or for advisory activities from CSL Behring, Dr. R. Pfleger, MOXIE, Novartis, Shire/Takeda, Uriach, UCB, and Viropharma. M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Astria, Allakos, Alnylam, Amgen , Aralez, ArgenX, AstraZeneca , BioCryst , Blueprint, Celldex , Centogene, CSL Behring , Dyax, FAES , Genentech , GIInnovation, GSK , Innate Pharma, Kalvista, Kyowa Kirin , Leo Pharma, Lilly , Menarini, Moxie, Novartis , Pfizer , Pharming, Pharvaris, Roche , Sanofi / Regeneron , Shire / Takeda , Third Harmonic Bio, UCB , and Uriach, all outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Chronic Urticaria Registry ( CURE ) has been funded by the Urticaria Network e.V. (a German nonprofit organization), the European Academy of Dermatology and Venereology (proposal number 2014-013), Novartis , and Uriach. Sponsors have not been involved in the design or implementation of CURE .
DFG-Fachsystematik
- 2.22-19 Dermatologie
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
